Grünenthal closes deal to acquire testosterone therapy NebidoTM from Bayer for €495 million
Aachen, Germany (ots) - Grünenthal today announced the successful completion of its acquisition of NebidoTM from Bayer for €495 million. "Testosterone deficiency affects one in six men over 50 years1; representing a significant burden," said Gabriel Baertschi, CEO Grünenthal. "With the completion of this deal, we can now work to bring this meaningful treatment to ...